Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
5μg/ml ESAT6-CFP10
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tuberculosis
1 trial -
5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tuberculosis
1 trial -
68Ga-NODAGA-SNA006
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cancer
1 trial -
ADSC01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Connective Tissue Diseases
1 trial -
AK104
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Resectable Non-small Cell Lung Cancer
1 trial -
AK117
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinoma
1 trial -
ASC30 tablets
Xiyuan Hospital of China Academy of Chinese Medical Sciences
T2DM (Type 2 Diabetes Mellitus)
1 trial -
ASCT+CD7-CART
Xiyuan Hospital of China Academy of Chinese Medical Sciences
CD7 Positive
1 trial -
AUY922
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastrointestinal Stromal Tumor
1 trial -
Abemaciclib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Liver Metastases From Colorectal Cancer (mCRC)
1 trial -
Abiraterone Acetate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prostate Cancer
1 trial -
Acetohydroxamic Acid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multidrug-Resistant Tuberculosis
1 trial -
Ad-HGF
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ischemic Heart Disease
1 trial -
Adebrelimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatic Cancer
1 trial -
Adebrelimab (PD-L1 inhibitor)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatic Cancer Metastatic
1 trial -
Ademetionine 1,4-Butanedisulfonate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Obstructive Hypertrophic Cardiomyopathy (oHCM)
1 trial -
Albumin Paclitaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Small Cell Lung Cancer
1 trial -
Alectinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Bone Cancer
1 trial -
Allogeneic MSC (AlloMSC)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Refractory Systemic Lupus Erythematosus
1 trial -
Almonertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Almonertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer Non-small Cell Stage IV
1 trial -
Anlotinib combined Docetaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Anrotinib plus Tirelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Anti-BCMA-CAR-transduced T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Leukemia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources